SCHEMBL22198165

SCHEMBL22198165

CN(C)c1ccc(/C=N/N=C/c2ccc(N(c3ccccc3)c3ccccc3)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.61
▸ KMT2A Q03164 8/20 0.61
▸ SMN1; SMN2 Q16637 6/20 0.61
▸ MAPT P10636 6/20 0.61
▸ MEN1 O00255 6/20 0.61
▸ NPC1 O15118 4/20 0.61
▸ RAB9A P51151 4/20 0.61
▸ L3MBTL1 Q9Y468 3/20 0.61
▸ KDM4E B2RXH2 2/20 0.61
▸ GLA P06280 1/20 0.61
▸ RELA Q04206 1/20 0.55
▸ GRIN2D O15399 2/20 0.54
▸ GRIN3B O60391 2/20 0.54
▸ GRIN1 Q05586 2/20 0.54
▸ GRIN2A Q12879 2/20 0.54
▸ GRIN2B Q13224 2/20 0.54
▸ GRIN2C Q14957 2/20 0.54
▸ GRIN3A Q8TCU5 2/20 0.54
▸ MCL1 Q07820 1/20 0.54
▸ G6PC1 P35575 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22198159 0.90 ALDH1A1 (0.67) ALDH1A1KMT2ASMN1; SMN2MAPTMEN1
SCHEMBL11123647 0.90 ALDH1A1 (0.67) ALDH1A1KMT2ASMN1; SMN2MAPTMEN1
SCHEMBL22198151 0.90 L3MBTL1 (0.61) ALDH1A1KMT2ASMN1; SMN2MAPTMEN1
SCHEMBL10909091 0.86 GRIN2D (0.68) ALDH1A1KMT2ASMN1; SMN2MAPTMEN1
SCHEMBL22198126 0.86 GRIN2D (0.68) ALDH1A1KMT2ASMN1; SMN2MAPTMEN1
SCHEMBL14423833 0.85 KMT2A (0.50) ALDH1A1KMT2ASMN1; SMN2MAPTMEN1
SCHEMBL279222 0.82 ALDH1A1 (0.61) ALDH1A1KMT2ASMN1; SMN2MAPTMEN1
SCHEMBL21173563 0.82 ALDH1A1 (0.61) ALDH1A1KMT2ASMN1; SMN2MAPTMEN1
SCHEMBL22198313 0.81 KMT2A (0.47) ALDH1A1KMT2ASMN1; SMN2MAPTMEN1
SCHEMBL22198164 0.81 ALDH1A1 (0.56) ALDH1A1KMT2ASMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210393810-A1 DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO A BETA PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF HTA Co., Ltd. (CN) 2021-12-23 — — US disclosed
WO-2020140924-A1 DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO AΒ PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF 原子高科股份有限公司 2020-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210393810-A1 DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO A BETA PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF MAPT, APP, PSEN1 ALDH1A1 1343/4885KMT2A 4397/4885SMN1; SMN2 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback